Clinical Trials
6 trialsNCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT01466153 2017-05-31
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC
Phase 2 Completed
NCT01088984 2016-05-23
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT01657955 2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown